About this Research Topic
Several biologically active sphingolipids, like the key metabolite ceramide and sphingosine-1-phosphate (S1P), have been found to play essential parts in the pathophysiology of various human diseases, such as Alzheimer's disease, insulin resistance and diabetes, cancer, and cardiovascular diseases. Imbalances of these biologically active lipids have been implicated as being the core component of disease pathogenesis. On the other hand, the sphingomyelin (SM) pathway represents a potential value and crucial point of immunoregulation therapy, such as enhancing T cell activity in tumor elimination or downregulating lymphocyte function in autoimmune diseases. Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.
This Research Topic aims to enhance our understanding of the mechanisms of sphingolipid metabolism and signalling in human diseases. We welcome Original Research, Reviews, Short Perspectives, and Expert Opinions that discuss any controversial topics related to sphingolipid signalling, including but not limited to the followings:
• Mechanisms by which sphingolipids influence the occurrence and progression of different diseases.
• Interaction between sphingolipids and immune cells revealed by Single-Cell Analysis and Multi-Omics.
• Application of sphingolipids in the diagnosis and treatment of various diseases.
• Crosstalk between sphingolipids and other metabolic molecules, and the role of the crosstalk in the diagnosis and treatment of different diseases.
• Application of machine learning in identifying effective sphingolipid biomarkers and corresponding sphingolipid molecular compounds in various diseases.
• Identification of sphingolipid agonists or antagonists and elucidation of their novel mechanisms of action.
Keywords: drug development, sphingolipid, biomarker
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.